We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of nex... Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others. Show more
CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth. The...
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced that Regina Graul, Ph.D., has been promoted to Chief Executive Officer...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0702 | -2.02305475504 | 3.47 | 3.79 | 2.8 | 241277 | 3.07120818 | CS |
4 | 1.9798 | 139.422535211 | 1.42 | 9.4699 | 1.27 | 9053661 | 5.52352959 | CS |
12 | 0.7098 | 26.3866171004 | 2.69 | 9.4699 | 1.27 | 3256077 | 5.30245818 | CS |
26 | 1.2098 | 55.2420091324 | 2.19 | 9.4699 | 1.27 | 1529635 | 5.29728817 | CS |
52 | -1.4802 | -30.3319672131 | 4.88 | 9.4699 | 1.27 | 778411 | 5.29351876 | CS |
156 | -32.4002 | -90.5033519553 | 35.8 | 37.8 | 1.27 | 362344 | 7.87088367 | CS |
260 | -40.6002 | -92.2731818182 | 44 | 179.2 | 1.27 | 452401 | 42.35496776 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions